COMP <GO>
BTSG vs ABBV // ENTERPRISE SCALE & MARKET CAP
BrightSpring Health Services Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: BTSG 3
— ABBV 11
▲ ENTERPRISE SCALE & MARKET CAP LEADER: ABBV
LAST: $66.89 (+11.08%) • MKT CAP: $11.92B
market-cap
$11.92B
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
market-cap
$513.86B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BTSG VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BTSG | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 11.80% | 70.20% | -58.40 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 5.50% | 29.00% | -23.50 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 37.9x | 33.3x | +4.60 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 3.31% | 3.47% | -0.16 | ABBV | /fcf-yield <GO> |
| Operating Margin | 2.30% | 24.60% | -22.30 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 1.50% | 6.90% | -5.40 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 28.20% | 8.60% | +19.60 | BTSG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.92 | 5.33 | -1.41 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 7.40% | -0.70 | BTSG | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.3 | 72.8 | -5.52 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.94 | 1.15 | -0.21 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 52.9x | 113.1x | -60.20 | BTSG | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $11.92B | $513.86B | -$501.94B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BTSG REV | ABBV REV | BTSG GROSS % | ABBV GROSS % | BTSG FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $12.91B | $61.16B | 11.8% | 70.2% | $394.7M | $17.82B |
| FY 2024 | $10.07B | $56.33B | 12.6% | 70.0% | -$57.1M | $17.83B |
| FY 2023 | $7.69B | $54.32B | 44.0% | 44.0% | -$135.3M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BTSG // BETA 0.94
ABBV // BETA 1.15